Skip to main content
. 2021 May 4;10(9):1099–1107. doi: 10.1002/cpdd.940

Table 4.

Summary of Adverse Events by Treatment (Safety Population)

Participants With Event, n (%) Placebo (N = 59) Atogepant 300 mg (N = 60) Moxifloxacin 400 mg (N = 59)
Any TEAE 3 (5.1) 1 (1.7) 8 (13.6)
Serious TEAE 0 0 0
Treatment‐related TEAE 0 0 0
TEAE leading to discontinuation 0 0 0

TEAE, treatment‐emergent adverse event.